Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials

Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials

Abstract Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin‐induced hearing loss (CIHL) is a common, clinically significant side effect with life‐long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two rece...

Full description

Bibliographic Details
Main Authors: Lori M. Minasian, A. Lindsay Frazier, Lillian Sung, Ann O’Mara, Joseph Kelaghan, Kay W. Chang, Mark Krailo, Brad H. Pollock, Gregory Reaman, David R. Freyer
Format: Article
Language:English
Published: Wiley 2018-07-01
Series:Cancer Medicine
Subjects:
cisplatin
hearing loss
pediatric
prevention
study design
Online Access:https://doi.org/10.1002/cam4.1563

Internet

https://doi.org/10.1002/cam4.1563

Similar Items